PSAvärden

PSAvärden is the concentration of prostate-specific antigen in the blood, used as a biomarker for prostate health. It is measured through a blood test and reported in nanograms per milliliter (ng/mL). In many adult men, lower PSAvärden values are considered normal, while higher values may indicate a greater risk of prostate pathology, including cancer. Age-specific reference ranges and different assay methods can influence the exact cutoffs.

In clinical practice, PSAvärden is used for several purposes. It can aid in initial screening for prostate cancer risk, inform decisions about whether a biopsy is warranted, and help monitor patients after treatment for prostate cancer to detect recurrence. Clinicians typically interpret PSAvärden alongside other factors, such as symptoms, imaging results, and other laboratory tests, rather than in isolation. Screening recommendations for PSA testing vary by country and guideline, emphasizing informed, shared decision-making.

PSAvärden is not cancer-specific. Elevated values can occur with benign prostatic hyperplasia, prostatitis, urinary tract infections, recent ejaculation, or recent prostate manipulation. Conversely, some cancers may not cause marked PSA elevation. Because PSA tests can lead to false positives and overdiagnosis, clinicians often consider additional metrics, such as PSA density (PSAD), PSA velocity (PSAv-velocity), or the fraction of free PSA, to refine risk assessment.

Overall, PSAvärden remains a widely used biomarker in urology for screening, diagnosis, and monitoring, interpreted within the broader clinical context.